Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Eur Respir J 2014; 43: 24–35 | DOI: 10.1183/09031936.00113413
"Patient decontamination principles are set forth here from a strategic perspective, rather than a tactical
one. The principles are meant to guide, but not specify, operational practices. The guidance is evidencebased
to the extent possible and the supporting evidence is documented and briefly dis...cussed."
more
Plos Neglected Tropical Diseases 8(11): e3229 (20 November 2014)
Please read online the lastest updated versions http://www.cdc.gov/vhf/ebola/qa.html
Lessons learned from an M&E task-shifting initiative in Botswana
This report has been developed, based on data provided by the TB & ORD surveillance system from across Rwanda. It provides a comprehensive picture of the occurrence and management of TB & ORD and Leprosy in Rwanda. It is structured based on the 2013-2018 Rwanda TB national strategic plan (2013-2018 ...TB NSP) and on the 2014-2018 Rwanda Leprosy national strategic plan (2014-2018 Leprosy NSP).
more
This document provides a summary of the recommendations for hand hygiene best practices to be performed by health workers providing care and/or support to patients with filovirus infection (Ebola and Marburg viruses).
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda